← Back to all signals
RESEARCH PAPER ANALYSIS

A Mega-Analysis of Anti-Müllerian Hormone Levels in Female Childhood Cancer Survivors Based on Treatment Risk, Time since Treatment, and Pubertal Status.

AI interpretation is pending for this paper.

Open original publication →
PMID39308417
JournalJournal of adolescent and young adult oncology
Publication Date2024-09-23
Ingested2026-08-02 12:02 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

Purpose: Female childhood cancer survivors (CCSs) risk infertility due to gonadotoxic chemotherapy/radiation. Anti-Müllerian hormone (AMH) helps evaluate ovarian reserve, and the 2020 Oncofertility Pediatric Initiative Network (O-PIN) risk stratification is utilized to counsel risk of gonadal dysfunction/infertility. This study analyzed how AMH levels after cancer treatment differ with age and correlate AMH with O-PIN risk level and clinical outcomes. Methods: A literature review and mega-analysis of individual patient data were performed. Females ages 0-20 years at the time of cancer diagnosis with AMH values post-treatment were included. AMH outcomes were compared by O-PIN risk stratification, age at diagnosis, cyclophosphamide equivalent dose (CED), and hematopoietic stem cell transplant (HSCT). Multivariable random effects mixed models correlated AMH with diminished ovarian reserve (DOR), premature ovarian insufficiency (POI), and pregnancy. Results: In 13 studies with 608 CCSs, the median age (years) at diagnosis was 12.0 (interquartile range [IQR] 5.2-16.2) and 21.1 (IQR 17.1-30.0) at AMH measurement. AMH values were higher with time since treatment and correlated with the O-PIN risk level. Patients with HSCT had very low/undetectable AMH levels regardless of CED; when stratified by CED, AMH levels were lower if treated peripubertally or older. AMH was detectable in 54% (34/63) of patients with POI on hormone replacement. Pregnancy did not correspond to the gonadotoxicity risk level (p = 0.70). Conclusion: This study supports utilizing the O-PIN risk stratification system in estimating risk of DOR in CCSs and its categorization by pubertal status. AMH levels may return over time even after receiving the highest risk therapy. These findings may help counsel cancer patients pre- and post-therapy.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Endoscopic Endonasal Resection of Sphenoid Sinus Craniopharyngioma in a Pediatric Patient. The Journal of craniofacial surgery 45.5 2 Single-Port Endoscopic Approach for Benign Tumors in the Lower Half of Forehead: A Comprehensive Surgical Algorithm. The Journal of craniofacial surgery 66.5 3 Association of Tear and Serum Proteomic Profile on Disease Severity in Vernal Keratoconjunctivitis (VKC). Romanian journal of ophthalmology 66.1 4 Probable primary bloodstream infection caused by multidrug-resistant Achromobacter piechaudii in an apparently immunocompetent child: a case report. BMC pediatrics 54.46 5 Understanding HPV vaccination communication needs of parents of Turkish and Moroccan origin living in the Netherlands: a qualitative study. BMC public health 56.0 6 Development and evaluation of a breast cancer risk stratification tool for women in Macau. BMC public health 79.0 7 Hepatic mesothelial cyst in an infant with Beckwith-Wiedemann syndrome and omphalocele - a case report. BMC surgery 47.5 8 Prenatal testing and postpartum treatment for hepatitis C virus among women with opioid use disorder. Obstetrics and Gynecology: Open Access 65.34 9 The Effect of Counseling Based on Watson's Human Caring Theory (HCT) on Reproductive Concerns in Women Diagnosed With Cancer: A Randomized Controlled Trial. Psycho-oncology 80.4 10 Acceptance and Commitment Therapy for Children, Adolescents, and Young Adults With Cancer and Their Parents and for Children, Adolescents, and Young Adults Affected by Parental Cancer: A Population-Stratified Systematic Review. Brain and behavior 80.24 11 Steroid-Related Neuropsychiatric Symptoms (SRNS) in Children with Acute Lymphoblastic Leukemia (ALL): A Systematic Review of Clinical Features, Risk Factors, and Management. Cancer management and research 86.9 12 Genetic determinants of chemotherapy-induced oral mucositis in children with solid malignancies. Pharmacogenomics 69.94 13 Phagocytosis activity is retained by JMML macrophages and increased by CD47 inhibition. British journal of haematology 52.5 14 Far Medial Endoscopic Transcervical Approach for Excision of a Recurrent Clival Chordoma Involving the Parapharyngeal and Prevertebral Spaces. Head & neck 60.8 15 The role of early maladaptive schemas and acceptance regarding chronic fatigue in oncology patients after treatment. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 68.24 16 Molecular Diagnostics and Clinicopathologic Spectrum of Kinase Fusion-Positive Spindle Cell Neoplasms of the Oral and Maxillofacial Region: A Systematic Review and Pooled Patient-Level Analysis. Head and neck pathology 74.5 17 Investigating the Effect of Synbiotic Supplementation on Inflammatory Indices in Critically Ill Septic Children: a Triple Blind Randomized Controlled Trial. Probiotics and antimicrobial proteins 80.6 18 A "Hot" Sulfur Colloid Clue in a Hypervascular Pediatric Liver Mass: Resolving a Large Focal Nodular Hyperplasia Mimicking Fibrolamellar Hepatocellular Carcinoma. Clinical nuclear medicine 55.2 19 Outcomes of Proton Beam Therapy in Infants and Very Young Children. Practical radiation oncology 70.94 20 Nanotechnology-enabled drug delivery for retinoblastoma: formulation strategies, ocular targeting and translational perspectives. Nanomedicine (London, England) 74.0 21 Peritoneal metastasis of histone 3 lysine 27-to-methionine-mutant diffuse midline glioma via ventriculoperitoneal shunt: laparoscopic confirmation of occult disease and the need for multimodal liquid biopsy. BMJ case reports 28.5 22 Avoid, repair, tolerate: emerging mechanisms of MAP therapy resistance in osteosarcoma. Biological chemistry 73.79 23 Patient reimbursement in therapeutic cancer clinical trials: An 18-year multicenter experience. Cancer 76.64 24 Sensitive LC-MS/MS Method for Simultaneous Quantification of Alectinib and Its Major Metabolite M4 in Limited-Volume Human Plasma. Biomedical chromatography : BMC 72.3 25 Mapping intratumoral heterogeneity in adolescent CNS tumors using simultaneous amide proton transfer-weighted signal and 18F-choline PET: A feasibility study. Neuro-oncology advances 57.5 26 Metastatic Neuroblastoma Presenting as Suspected Septic Arthritis: A Case Report. Cureus 52.3 27 Functional Impairment and Its Determinants in Adolescents With Inherited Bleeding Disorders: A Single-Centre Cross-Sectional Study. Cureus 62.0 28 A multimodal precision oncology platform integrating genomics, single-cell transcriptomics, and functional drug screening expands therapeutic options in pediatric brain tumors. bioRxiv : the preprint server for biology 69.2 29 Epigenetic patterns and methylation-based models for robust outcome prediction in osteosarcoma. medRxiv : the preprint server for health sciences 60.8 30 Association of Neuronal Cell Adhesion Molecule (NrCAM) Gene with Autism Spectrum Disorder in Indian Cohorts. Annals of neurosciences 60.0 31 State of Precision Oncology: An Australian Perspective. Journal of immunotherapy and precision oncology 72.9 32 Malignant Giant Cell Tumor of Bone: A Clinicopathological Analysis of 15 Cases. Human mutation 61.1
PATIENT-FRIENDLY SUMMARY

A Mega-Analysis of Anti-Müllerian Hormone Levels in Female Childhood Cancer Survivors Based on Treatment Risk, Time since Treatment, and Pubertal Status.

For education only—not personal medical advice.

Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic